Camp4 Therapeutics CAMP 深 沪
已收盘 10-02 16:00:00 美东时间
4.00
+0.160
+4.17%
华盛通- 最 高4.05
- 今 开3.90
- 成交量 36.80万股
- 最 低 3.69
- 昨 收 3.84
- 总市值 25.10万
- 52周最高 7.75
- 市盈率 静 --
- 换手率 586.35%
- 52周最低 2.86
- 委 比 22.03%
- 总股本 6.28万
- 历史最高 12.30
- 量 比 0.95
- 振 幅 9.38%
- 历史最低 0.40
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.
09-29 20:11
CAMP4 Details ASCEND Trial Plans in SYNGAP1 Disorder
CAMP4 Therapeutics Corporation ( ($CAMP) ) has shared an update. On September 2...
09-29 05:25
CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder
CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will...
09-09 04:09
CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026
CAMP4 Therapeutics will host a virtual Analyst Day on September 28, 2026, to discuss SYNGAP1-related disorder and its lead candidate CMP-002, a potential disease-modifying therapy. The event will feature presentations on the clinical trial design for the first-in-human Phase 1/2 trial of CMP-002, expected to begin in Q4 2026, as well as updates on the company's early discovery pipeline. Stéphane Auvin, MD, Ph.D., a leading expert in pediatric epi...
09-08 20:05
CAMP4 to Participate in Upcoming Investor Conferences
CAMP4 Therapeutics Corporation will participate in two upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, in Boston, and the Cantor Global Healthcare Conference on September 9, 2026, in New York. The latter will include a fireside chat and one-on-one meetings, with a webcast available. CAMP4 focuses on developing RNA-targeting therapeutics to upregulate gene expression and treat genetic diseases...
09-01 20:05
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15
Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.
08-15 00:22
Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $1.779 mi...
08-14 04:34
CAMP4 Therapeutics Secures $50 Million Private Financing
CAMP4 Therapeutics Corporation ( ($CAMP) ) has issued an update. On August 3, 2...
08-04 19:29
